Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on PDS Biotechnology, retaining the price target of $13.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis’s rating is based on the promising advancements and potential of PDS Biotechnology’s therapeutic developments. The company has achieved a significant milestone in its clinical trial for PDS01ADC, a treatment for metastatic colorectal cancer, by meeting the criteria for expansion into the second stage of the study. This progress indicates the potential for PDS01ADC to become a significant player in solid tumor intervention, offering both commercial and value-generating opportunities for the company and its investors.
Additionally, the encouraging data from the Versamune HPV treatment, particularly in the context of HPV16+ head and neck squamous cell carcinoma, further supports Pantginis’s positive outlook. The combination of Versamune HPV with pembrolizumab has shown promising results, exceeding current benchmarks in clinical activity and durability. This positions the treatment well for success in ongoing trials, further enhancing the company’s growth prospects and justifying the Buy rating.